Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ELVN on Nasdaq
Shares outstanding
58,923,077
Price per share
$25.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
62,302,098
Total reported value
$959,455,470
% of total 13F portfolios
0%
Share change
+2,258,428
Value change
+$20,206,651
Number of holders
124
Price from insider filings
$25.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 13% $140,468,212 7,918,163 ORBIMED ADVISORS LLC 16 Jun 2025
FMR LLC 13% $161,103,383 7,870,219 FMR LLC 30 Sep 2025
Commodore Capital LP 9.9% $135,215,385 6,022,957 Commodore Capital LP 30 Jun 2025
Vestal Point Capital, LP 6.5% $98,622,500 3,830,000 Vestal Point Capital, LP 31 Dec 2025
Fairmount Funds Management LLC 6.3% -4.3% $83,321,918 +$11,419,103 3,711,444 +16% Fairmount Funds Management LLC 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 5.4% $66,042,996 3,226,331 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
BlackRock, Inc. 5.1% $59,005,266 2,941,395 BlackRock, Inc. 30 Jun 2025
Polar Capital Holdings Plc 5.2% +5.6% $56,952,978 +$3,304,932 2,536,881 +6.2% Polar Capital Holdings Plc 30 Jun 2025

As of 31 Dec 2025, 124 institutional investors reported holding 62,302,098 shares of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN). This represents 106% of the company’s total 58,923,077 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) together control 96% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 14% 7,959,538 0% 2.6% $122,576,885
FMR LLC 12% 7,107,635 -0.3% 0.01% $109,457,572
Commodore Capital LP 8% 4,692,809 0% 4.8% $72,269,259
Vestal Point Capital, LP 6.5% 3,830,000 +230% 2.2% $58,982,000
Fairmount Funds Management LLC 6.3% 3,711,444 0% 4.4% $57,156,238
BlackRock, Inc. 6.1% 3,613,326 +2.7% 0% $55,645,219
Polar Capital Holdings Plc 6% 3,513,680 +14% 0.25% $54,110,672
VR ADVISER, LLC 5.5% 3,226,331 0% 2.5% $49,685,497
VANGUARD GROUP INC 4.8% 2,801,665 +9.7% 0% $43,145,640
JANUS HENDERSON GROUP PLC 2.8% 1,671,724 -6.8% 0.01% $25,744,550
Point72 Asset Management, L.P. 2.6% 1,504,601 +45% 0.04% $23,170,855
NOVO HOLDINGS A/S 2.5% 1,480,000 +3.8% 1.8% $22,792,000
CITADEL ADVISORS LLC 2.4% 1,424,344 +23% 0.01% $21,934,897
Capital Research Global Investors 2.2% 1,304,346 -0.85% 0% $20,086,928
Pictet Asset Management Holding SA 2.2% 1,303,235 -6.8% 0.02% $20,069,819
STATE STREET CORP 1.8% 1,052,862 +9.1% 0% $16,214,075
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,048,722 -3.3% 0% $16,153,779
Soleus Capital Management, L.P. 1.7% 1,025,000 0.67% $15,785,000
Blackstone Inc. 1.6% 954,946 -28% 0.06% $14,706,168
Rock Springs Capital Management LP 1.4% 798,405 +16% 0.63% $12,295,437
5AM Venture Management, LLC 1.3% 772,477 0% 3.7% $11,896,146
Candriam S.C.A. 0.77% 453,019 -26% 0.03% $6,976,790
Spruce Street Capital LP 0.76% 446,084 0% 2.3% $6,869,694
MORGAN STANLEY 0.7% 411,823 +59% 0% $6,342,080
DIMENSIONAL FUND ADVISORS LP 0.68% 398,893 +149% 0% $6,143,418

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 62,302,098 $959,455,470 +$20,206,651 $15.40 124
2025 Q3 59,389,507 $1,215,687,864 -$296,038 $20.47 132
2025 Q2 59,434,902 $1,192,251,085 +$192,194,924 $20.06 123
2025 Q1 49,886,849 $983,923,667 +$4,352,699 $19.68 118
2024 Q4 49,624,914 $1,116,597,658 +$24,828,957 $22.50 111
2024 Q3 47,688,348 $1,218,010,157 -$20,810,259 $25.54 100
2024 Q2 48,318,843 $1,129,194,355 +$91,652,714 $23.37 91
2024 Q1 44,456,336 $780,753,492 +$95,045,035 $17.59 72
2023 Q4 39,000,634 $539,791,932 -$652,659 $13.84 61
2023 Q3 39,076,502 $533,779,750 -$2,178,662 $13.66 60
2023 Q2 39,092,843 $797,915,923 +$112,876,379 $20.41 61
2023 Q1 33,557,749 $734,910,999 +$734,911,000 $21.90 44